The main aim in treating hepatitis C virus (HCV) infection is to achieve a sustained virological response (SVR). It is defined as undetectable HCV-RNA in peripheral blood 24 weeks after the end of treatment. The RNA is detected by polymerase chain reaction (PCR) technique. The SVR practically reflects eradication of HCV infection and cure of the underlying HCV-induced liver disease. Treatment of HCV-induced chronic hepatitis includes one of the available Interferon-alpha (INF-alpha) in combination with Ribavirin (RBV). To achieve much better results, combination of PEG-INF with RBV is currently recommended. This regimen is quite effective in treating HCV genotype 2 and 3 but much less so in genotypes 1 and 4. At the same time it has long been observed that these combinations have sometimes severe side effects and contraindications limiting their efficacy and applicability in a significant number of chronic HCV patients. Therefore, the importance of improving existing therapies and developing new, effective, safe and tolerable drugs is well appreciated, worldwide. This review describes improvements in the current standard therapy and new emerging drugs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Homelessness and Birth Outcomes in the Pregnancy Risk Assessment Monitoring System, 2016-2020.
Matern Child Health J
January 2025
Office of the Director, Office of Readiness and Response, CDC, Atlanta, GA, USA.
Objectives: This study aimed to estimate the prevalence of homelessness shortly before or during pregnancy and describe differences in maternal characteristics and adverse birth outcomes between people reporting homelessness and not reporting homelessness.
Methods: We used 2016-2020 Pregnancy Risk Assessment Monitoring System (PRAMS) data from 31 sites to estimate the prevalence of self-reported homelessness during the 12 months before giving birth. We used logistic regression models to evaluate the association between homelessness and adverse birth outcomes, specifically small for gestational age (SGA), low birth weight (LBW), and preterm birth (PTB).
Editorial: HBeAg-Positive Chronic Hepatitis B With Low HBsAg Levels-Exploring Clinical Significance of preS2 Deletion Mutations.
Aliment Pharmacol Ther
January 2025
School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Editorial: HBeAg-Positive Chronic Hepatitis B With Low HBsAg Levels-Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply.
Aliment Pharmacol Ther
January 2025
Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Porous Silicon Particle-Assisted Mass Spectrometry Technology Unlocks Serum Metabolic Fingerprints in the Progression From Chronic Hepatitis B to Hepatocellular Carcinoma.
ACS Appl Mater Interfaces
January 2025
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, China.
Hepatocellular carcinoma (HCC) is a common malignancy and generally develops from liver cirrhosis (LC), which is primarily caused by the chronic hepatitis B (CHB) virus. Reliable liquid biopsy methods for HCC screening in high-risk populations are urgently needed. Here, we establish a porous silicon-assisted laser desorption ionization mass spectrometry (PSALDI-MS) technology to profile metabolite information hidden in human serum in a high throughput manner.
View Article and Find Full Text PDFCurrent status of drug therapy for chronic hepatitis B.
World J Gastroenterol
January 2025
Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
In this editorial, we comment on the article by Meng . Chronic hepatitis B (CHB) is a significant global health problem, particularly in developing countries. Hepatitis B virus (HBV) infection is one of the most important risk factors for cirrhosis and hepatocellular carcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!